Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 2:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2425–2448 of 2,513 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: RAPID Clear all

Conditions: Aging, Cognitive Change
Interventions: Adaptive Cognitive Control Trainer (ACCT), Active Control App; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 50 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Kidney Failure, Chronic, End-Stage Kidney Disease, Renal Failure, Chronic, Renal Failure, End-Stage, Healthy Participants
Interventions: MK-5684, Prednisone, Fludrocortisone acetate; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 85 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 2
States / cities: Orlando, Florida • Chicago, Illinois

Conditions: Healthy
Interventions: 10 mg dose MR formulations,10 mg dose of tofacitinib IR solution; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hypoxia
Interventions: Injectafer, Placebo; Drug · Other
Lead sponsor: United States Army Research Institute of Environmental Medicine; Federal
Eligibility: 18 Years to 40 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Natick, Massachusetts

Conditions: Multiple Sclerosis
Interventions: Rituximab Infusion; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 80 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Healthy Volunteers
Interventions: GCC-4401C, Rivaroxaban, Placebo; Drug
Lead sponsor: Green Cross Corporation; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Early Phase Clinical Unit _Los Angeles, California

Conditions: Intubation Complication
Interventions: Not listed
Lead sponsor: New York City Health and Hospitals Corporation; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Timeline: 2017
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: COVID-19
Interventions: Covid-19 Antibody Test, Short Clip videos; Diagnostic Test · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 327 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Greensboro, North Carolina

Conditions: Cancer, Pediatric Cancer
Interventions: Questionnaire, Physical Exam; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 30 Days to 30 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Aurora, Colorado • Portland, Oregon

Conditions: Persistent Post Operative Opioid Use, Post-surgical Pain
Interventions: PGx guided personalized post-operative pain management, Oxycodone, Hydromorphone; Other · Drug
Lead sponsor: University of Tennessee Graduate School of Medicine; Other
Eligibility: 18 Years to 85 Years
Enrollment: 208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Cervical Cancer, Uterine Endometrial Cancer, Ovarian Cancer
Interventions: Laparotomy, intravenous narcotics, standard anesthesia, regional anesthesia, Non-steroidal anti-inflammatory drugs; Procedure · Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 19 Years and older
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Adenovirus Infection, Epstein-Barr Virus Infections, Cytomegalovirus Infections, Stem Cell Transplant
Interventions: Multi-virus Specific T cells; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Opioid-use Disorder
Interventions: Vivitrol, Buprenorphine; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Bipolar Depression
Interventions: Coenzyme Q10; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 55 Years to 89 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Brain Metastases From HER2 and Breast Cancer, Advanced HER2-positive Breast Cancer
Interventions: ARRY-380 Twice Daily Dosage, ARRY-380 Once Daily, Trastuzumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Anesthesia, Local
Interventions: LET Gel after STAR Particle Application (Right or Left Arm), LET Gel Application without STAR Particle Application (Contralateral Arm); Device · Other
Lead sponsor: Emory University; Other
Eligibility: 10 Years to 21 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Tobacco Use Cessation
Interventions: Patient Outcomes, Billing documentation, Regulatory; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 12 Years and older
Enrollment: 54,417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Renal Impairment, Disease Severity
Interventions: Lenvatinib; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee

Conditions: Autism
Interventions: Not listed
Lead sponsor: Northeastern University; Other
Eligibility: 5 Years to 20 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Harris, New York

Conditions: COVID-19 Virus Infection, COVID-19, Coronavirus Disease-19, COVID-19 Pandemic, SARS-CoV-2 Infection
Interventions: iStatis COVID-19 Ag Rapid Test, "COVID-19 RT-PCR Test EUA Number: EUA200011, Company: Laboratory Corporation of America ("Labcorp"); Diagnostic Test
Lead sponsor: bioLytical Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Fort Lauderdale, Florida • Elkridge, Maryland

Conditions: Anxiety
Interventions: FW-200; Device
Lead sponsor: Fisher Wallace Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Atlanta, Georgia • Seattle, Washington

Conditions: HIV Infections
Interventions: In Vitro Diagnostic Device; Device
Lead sponsor: Chembio Diagnostic Systems, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 2,808 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 5
States / cities: La Jolla, California • Fort Lauderdale, Florida • Baltimore, Maryland + 2 more

Conditions: Healthy
Interventions: Pregabalin ER; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Implant or Graft; Rejection
Interventions: Belatacept, Tacrolimus, Mycophenolate, rATG, Methylprednisolone, Renal transplant; Drug · Procedure
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Enhancing Cognitive Control Abilities Using Mobile Technology in a Senior Living Community

A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)

PK Study in Adult Healthy Volunteers to Assess QD Dosing With the Selected Age-appropriate MR Formulations

Intravenous Iron Effects on Performance at High Altitude

Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases

A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy Volunteers

End-tidal Oxygen Can Reliably Predict the Arterial Partial Pressure of Oxygen Among Emergency Department Patients

RADx-UP CDCC Rapid Research Pilot Program "Culturally-relevant Community Connections (C3) to Increase COVID-19 Testing

Integrative Health Interventions in Symptom Management of Pediatric Patients

Personalized Post-Operative Pain Management

Implementation of a Rapid Recovery Program in Gynecologic Oncology Surgery: A Pilot Study

Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE)

A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine Responders

Exploring the Effects of Coenzyme Q10 on Bioenergetics Metabolism in Geriatric Bipolar Depression

ARRY-380 + Trastuzuamab for Breast w/ Brain Mets

Lidocaine Administration Using STAR Particles

Optimizing the Tobacco Cessation Clinical Decision Support Tool.

A Phase 1, Open-Label, Single-Dose, Pharmacokinetic and Safety Study of E7080 (24 mg) Administered to Subjects With Mild, Moderate, and Severe Renal Impairment and to Healthy Subjects

MENTIS Personal Health Record Rapid Pilot Research Deployment and Evaluation

Evaluation of Clinical Performance and Usability of iStatis COVID-19 Ag Rapid Test at POC

A Study Comparing Immediate Treatment to Deferred Treatment With the Fisher Wallace (FW) Stimulator FW-200 Device for the Treatment of Self-reported Anxiety in First Responders

Evaluation of the Performance of Chembio Diagnostics Systems, Inc. DPP® HIV 1/2 Rapid Test

Bioavailability Study of Pregabalin Extended Release Formulation With Various Release Rates in Healthy Volunteers

Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients